Evidence map›Paper›PMID 39243345›Full record

ReviewCurrent atherosclerosis reports2024

Should We Use Aspirin or P2Y

Rishi Chandiramani, Adhya Mehta, Roger S Blumenthal, Marlene S Williams

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rishi Chandiramani, 600 N Wolfe St sted 560, Baltimore, MD, 21287, USA.
Adhya MehtaDepartment of Internal Medicine, Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, USA.
Roger S Blumenthal, 600 N Wolfe St sted 560, Baltimore, MD, 21287, USA.
Marlene S WilliamsDepartment of Medicine, Division of Cardiology, The Johns Hopkins University, 301 Mason Lord Drive, Suite 2400, Baltimore, MD, 21224, USA. mwillia1@jhmi.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewTo summarize the recent evidence and guideline recommendations on aspirin or P2Y RECENT

findingsIt has been questioned whether the evidence for aspirin as the foundational component of secondary prevention in patients with coronary artery disease aligns with contemporary pharmaco-invasive strategies. The recent HOST-EXAM study randomized patients who had received dual antiplatelet therapy for 6 to 18 months without ischemic or major bleeding events to either clopidogrel or aspirin for a further 24 months, and demonstrated that the patients in the clopidogrel arm had significantly lower rates of both thrombotic and bleeding complications compared to those in the aspirin arm. The patient-level PANTHER meta-analysis showed that in patients with established coronary artery disease, P2Y

Indexed as

AspirinMyocardial IschemiaPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsClopidogrelCoronary Artery DiseaseDual Anti-Platelet TherapyHemorrhageHumansSecondary PreventionAspirinClopidogrelPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsAntiplatelet therapyAspirinChronic coronary diseaseP2Y12 inhibitorStable ischemic heart disease

Identifiers

PMID39243345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.